A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

ClinicalTrials.gov ID: NCT07613294

Public ClinicalTrials.gov record NCT07613294. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a). Participation will last about 120 weeks.

Study identification

NCT ID: NCT07613294
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 252 participants

Conditions and interventions

Conditions

Interventions

Lepodisiran Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 45 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 1, 2026 (Actual)
Primary completion: Dec 2029 (Estimated)
Completion: Dec 2029 (Estimated)
Last update posted: Oct 8, 2026

2026 – 2029

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 17

Facility	City	State	ZIP	Site status
UCSD - Altman Clinical and Translational Research Institute (ACTRI)	La Jolla	California	92037-7410	Not yet recruiting
Valley Clinical Trials, Inc.	Northridge	California	91325	Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Torrance	California	90502	Recruiting
Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care	Fort Lauderdale	Florida	33312	Recruiting
Jacksonville Center for Clinical Research	Jacksonville	Florida	32216	Recruiting
Merritt Island Medical Research, LLC	Merritt Island	Florida	32952	Recruiting
Inpatient Research Clinic	Miami Lakes	Florida	33014	Recruiting
Clinical Site Partners, LLC dba Flourish Research	Winter Park	Florida	32789	Recruiting
High Desert Heart & Vascular	Meridian	Idaho	83642	Not yet recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Not yet recruiting
Profound Research LLC	Farmington Hills	Michigan	48334	Recruiting
Vector Clinical Trials	Las Vegas	Nevada	89128	Recruiting
Heart and Vascular Research at WellSpan Health	York	Pennsylvania	17403	Recruiting
Intermountain Medical Center	Murray	Utah	84107	Recruiting
Virginia Heart	Falls Church	Virginia	22042	Not yet recruiting
Carilion Clinic	Roanoke	Virginia	24014	Recruiting
Eastside Research Associates	Redmond	Washington	98052	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07613294, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07613294 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →